A Community-Based Chronic Pain Self-Management Program in West Virginia
A Randomized Controlled Trial of a Community-Based Chronic Pain Self-Management Program in West Virginia
Chronic pain (CP) affects 1 in 3 US adults and costs up to $635 billion annually in medical costs and lost work productivity. Use of opioid medications for CP has risen in the US, and opioid overdose deaths have quadrupled, yet with no overall change in pain. Although one-third of US adults have CP, there is a lack of affordable, non-pharmacological, evidence-based, community-delivered interventions for people with CP.
One program, the Chronic Pain Self-Management Program (CPSMP), provides short-term improvements in pain but its long-term effects have not been evaluated. This study will examine the long-term effects of CPSMP in the medically underserved state of West Virginia (WV). The objectives of this community-engaged, randomized, wait-list controlled study are to: 1) determine the short- (26 weeks) and long-term (52 weeks) effectiveness of the 6-week CPSMP in adults with CP in WV; 2) evaluate the Reach (number of participants, completers), Effectiveness (outcomes), Adoption (number of sites, leaders, trainings), Implementation (fidelity), and Maintenance (satisfaction, continuation) of CPSMP using the RE-AIM Framework; and 3) disseminate the results to key stakeholders including evidence-based organizations, public health practitioners/researchers, and healthcare providers.
The study will enroll 240 participants in 24 workshops at 12 community-based sites in 2 counties in WV, Greenbrier (rural) and Wood (urban). Participants will attend free, 2.5-hour weekly sessions for 6 weeks. Self-reported, performance-based, and physiological data will be collected at baseline and 26, and 52 weeks after the start of the intervention. The primary outcomes are pain (severity, quality, interference, medication use), mental health (mood, anxiety, catastrophizing), function (self-efficacy, coping, health-related quality of life, sleep, fatigue, communication, physical activity), healthcare utilization, missed work days, and gait speed.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Chronic pain (CP) affects 1 in 3 US adults and costs up to $635 billion annually in medical costs and lost work productivity. The impact of CP is worse in people with both CP and comorbid chronic diseases such as arthritis, diabetes, and heart disease. Use of opioid medications for CP has risen in the US, and opioid overdose deaths have quadrupled, yet with no overall change in pain. Although one-third of US adults have CP, there is a lack of affordable, non-pharmacological, evidence-based, community-delivered interventions for people with CP. Thus, there is a vital need to rigorously test more interventions that can be brought to scale and widely disseminated in the US.
One program, the Chronic Pain Self-Management Program (CPSMP), provides short-term improvements in pain but its long-term effects have not been evaluated. This study will examine the long-term effects of CPSMP in the medically underserved state of West Virginia (WV). With one of the worst health profiles in the US, WV has the highest rates of arthritis, diabetes, heart disease, and drug overdose deaths, and therefore has a compelling need for the CPSMP. The objectives of this community-engaged, randomized, wait-list controlled study are to: 1) determine the short- (26 weeks) and long-term (52 weeks) effectiveness of the 6-week CPSMP in adults with CP in WV; 2) evaluate the Reach (number of participants, completers), Effectiveness (outcomes), Adoption (number of sites, leaders, trainings), Implementation (fidelity), and Maintenance (satisfaction, continuation) of CPSMP using the RE-AIM Framework; and 3) disseminate the results to key stakeholders including evidence-based organizations, public health practitioners/researchers, and healthcare providers.
The study will enroll 240 participants in 24 workshops at 12 community-based sites in 2 counties in WV, Greenbrier (rural) and Wood (urban). Participants will attend free, 2.5-hour weekly sessions for 6 weeks. Two trained leaders will facilitate group discussions on managing pain, emotions, depression, fatigue, and sleep; proper exercise, nutrition, and medication use; weight management; strategies for effective communication with healthcare professionals; evaluating treatments; and pacing/planning. Self-reported, performance-based, and physiological data will be collected at baseline and 26, and 52 weeks after the start of the intervention. The primary outcomes are pain (severity, quality, interference, medication use), mental health (mood, anxiety, catastrophizing), function (self-efficacy, coping, health-related quality of life, sleep, fatigue, communication, physical activity), healthcare utilization, missed work days, and gait speed.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
West Virginia
-
Lewisburg, West Virginia, Estados Unidos, 24901
- West Virginia School of Osteopathic Medicine
-
Parkersburg, West Virginia, Estados Unidos, 26101
- Mid-Ohio Valley Health Department
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults over age 18
- Have chronic pain (pain on most days or everyday) for the past 3 months or more
- Able to attend 1 CPSMP workshop a week over 6 weeks
- Able to attend 3-4 testing sessions for data collection (testing sessions are scheduled before the workshops begin and then six months, one year and, for those assigned to the control group, one and a half years after the start of the study)
Exclusion Criteria:
- Chronic pain caused by current cancer diagnosis or an open wound
- Lack reliable transportation
- Having surgery for the painful area in the next year
- Not community-dwelling (i.e., living in a nursing home, assisted living or personal care home, mental hospital, or correctional facility)
- Not willing to be randomized to either start CPSMP workshop now or in six months
- Participation in another self-management program (e.g., Diabetes Self-Management Program) in the past 12 months
- Unable to speak English
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: CPSMP Intervention
Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
|
Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
|
|
Comparador Ativo: Wait-list Control Group
Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
|
Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain severity
Prazo: Change between baseline and 52 weeks
|
Using Stanford's 0-10 Pain Visual Numeric Scale participants will rate their pain in the past 2 weeks on an 11-item scale ranging from 0 (no pain) to 10 (severe pain).
|
Change between baseline and 52 weeks
|
|
Defense and Veterans Pain Rating Scale
Prazo: Change between baseline and 52 weeks
|
Using the Defense and Veterans Pain Rating Scale will rate their pain in the past 2 weeks on an 11-item scale ranging from 0 (no pain) to 10 (severe pain).
|
Change between baseline and 52 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain interference with sleep
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Defense and Veterans Pain Rating Scale Supplemental Question (revised from 24 hours to past 2 weeks)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Pain frequency
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
2016 NHIS (past 3 months)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Perceived disability
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Pain Disability Index
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Pain avoidance
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Tampa Scale of Kinesiophobia.
A total score is calculated that ranges from 17 (low degree of kinesiophobia) to 68 (a high degree of kinesiophobia)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Opioid misuse
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Screener and Opioid Assessment for Patients with Pain (SOAPP) v1.0-SF
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Medication Usage
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Morphine milligram equivalents (MME) per day of current prescription or over-the-counter medications for pain, depression, anxiety, mood, or sleep (also usage of stimulants and muscle relaxers)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Mood
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Stanford Personal Health Questionnaire-Depression (PHQ-8)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Anxiety
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Generalized Anxiety Disorder-7 (GAD-7)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Catastrophizing
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Pain Catastrophizing Scale.
The total score ranges from 0 (low catastrophizing) to 52 (high catastrophizing).
There are 3 subscales (rumination, magnification, and helplessness)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Mindfulness
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
5 Facet Mindfulness Questionnaire Short Form
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Pain Self-Efficacy
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Pain Self-Efficacy Scale.
The total score ranges from 0 (low self-efficacy) to 60 (high self-efficacy)
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Coping
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Coping Strategies Questionnaire-Revised
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Activation
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Patient Activation Measure
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
General Health Status
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
2016 BRFSS question
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Vitality
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
SF-36 v1
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Minutes of Physical Activity
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
2016 NHIS questions
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
|
Healthcare Utilization
Prazo: Monthly for up to 12 months
|
Emergency room visits and doctor/clinic visits
|
Monthly for up to 12 months
|
|
Work
Prazo: Monthly for up to 12 months
|
Number of days missed work and number of days in bed more than half of the day
|
Monthly for up to 12 months
|
|
Gait speed
Prazo: Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
5- or 10-meter gait speed test
|
Data will be collected at baseline, 26 weeks after the start of the study and 52 weeks after the study start.
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 3U48DP005004-04S1 (Concessão/Contrato do NIH dos EUA)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .